Micro-gyroscopes can detect cancer

December 22, 2005

A vibrating disc no bigger than a speck of dust could help to diagnose and monitor common types of cancer and provide specialists with information about the most appropriate therapy.

The European Commission has this month awarded 12 million Euros to an international consortium led by Newcastle University, England, to develop the biosensor technology towards clinical trials stage.

The research team aims to produce a hand-held device which would enable samples of blood, smear or biopsy to be tested quickly and accurately, for signs of cancer of the breast, cervix, colon or rectum.

The device would identify 'cancer specific markers' - proteins or other molecules produced by cancer cells - which vary according to the type of cancer and are distinct from proteins produced by healthy cells.

The researchers have manufactured discs less than one-tenth of a millimetre in diameter and coated them with special patterns of DNA or proteins which cause the cancer-specific markers to bind to the surface.

The discs are created in a silicon wafer and made to vibrate electronically in two modes. When a cancer-specific marker binds to the surface of a disc, in the pattern of the coating, the uneven weight causes one of the modes of vibration to change in frequency.

The difference between the frequencies of the two modes of vibration is measured, enabling the detection of tiny amounts of cancer specific marker. In theory, even the weight of a single molecule binding to the surface of a disc could be detected.

Professor Calum McNeil, of the School of Clinical and Laboratory Sciences at Newcastle University, who is leading the project, said: 'We are confident that this new technology has the potential to improve the prospects of successful treatment for these cancers'.

'Early diagnosis and effective monitoring of cancers are known to be key factors influencing outcome. In addition, the technology could provide specialists with advice about the most appropriate therapy for a particular patient, since the devices could easily be connected to sources of information such as a hospital computer network, the internet or a mobile phone.'

Initial research was funded by the LINK Analytical Biotechnology Initiative, sponsored by the Biotechnology and Biological Sciences Research Council (BBSRC) and the Department of Trade and Industry.

The technology could eventually be developed for other types of cancer and a range of other diseases, including those caused by bacteria. This opens up the possibility of hospitals being able to screen new patients and visitors for MRSA, tuberculosis and other diseases to prevent the infections being carried into the wards.

Potential uses do not stop at medicine. In theory, the technology could be used to detect particles from biological or chemical weapons, providing an early warning system against terrorist attacks.

Professor McNeil collaborated closely with colleagues in engineering and life sciences at Newcastle University (further details in Notes for Editors). In fact, the idea of vibrating discs was inspired by earlier work at the University involving the manufacture of micro-gyroscopes, which are now standard equipment in many devices that detect movement, from navigation equipment to car air-bags.

At the heart of a micro-gyroscope is a vibrating disc that must be almost perfectly formed to operate correctly. Professor McNeil realised that a near-perfect disc could be turned into an extremely sensitive weighing machine because the addition of a tiny weight would make it vibrate unevenly.
-end-
European Commission funding for the project, known as Smart Integrated Biodiagnostic Systems for Healthcare, or SmartHEALTH for short, officially begins in December 2005, via the European Commission's Framework 6 programme.

The research consortium comprises four universities, seven research institutes, 11 SMEs (small to medium-sized enterprises), three large companies and four clinical centres in the UK, Germany, Netherlands, Spain, Belgium, Ireland, Switzerland, Italy, Norway, Sweden and Australia.

Newcastle University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.